Business Wire

NY-FINSBURY-GLOVER-HERNG

7.7.2020 12:02:08 CEST | Business Wire | Press release

Share
Finsbury, The Glover Park Group and Hering Schuppener to Form One Global Firm

Finsbury, The Glover Park Group (GPG) and Hering Schuppener are joining together to create the preeminent global strategic communications and public affairs consultancy. The new firm, Finsbury Glover Hering, will combine the complementary strengths of three of the world’s most respected advisory firms to counsel chief executives, boards and leaders at public and private companies, leading institutions and nonprofit organizations. The combination formalizes the strategic partnership between the three WPP companies, which was formed by Finsbury and Hering Schuppener in 2016 and which GPG joined in 2017.

At a time when companies and institutions face heightened expectations of purpose and transparency, as well as increased public and stakeholder scrutiny, Finsbury Glover Hering is uniquely equipped to provide integrated, tailored solutions to help organizations navigate the financial, legal, regulatory, societal and stakeholder complexities they must consider in shaping their communications. Clients will benefit from Finsbury Glover Hering’s global network of nearly 700 experts in 18 offices in the world’s major financial, government, business and cultural centers, where the firm builds on strong local foundations forged through decades of experience.

The new firm will lead the industry in:

  • Public affairs and issues management, with deep policy expertise, a reputation for results and unmatched networks in the world’s capitals;
  • Capital markets communications, having advised on more than 1,500 transactions with a total value of more than $2 trillion over the past decade alone; and
  • Corporate, crisis and transformation communications, successfully positioning CEOs and other leaders, steering major public and private companies through high-stakes moments of change and helping launch or re-launch organizations to industry leader status.

Finsbury Glover Hering will launch in early 2021. Finsbury founder Roland Rudd and GPG founder Carter Eskew will co-chair the new firm. Alexander Geiser, Managing Partner at Hering Schuppener, will serve as Chief Executive Officer with the support of seasoned global and regional management teams.

Finsbury Glover Hering will be driven by the highly entrepreneurial spirit that inspired its founder firms and intends to offer equity to recruit, retain and incentivize the best established and emerging talent in communications and public affairs. The management team will be investing in the new firm and will own 49.99% of the company alongside WPP, which will retain a majority interest. Mark Read, the CEO of WPP, will also join the Board of Directors of the newly integrated company.

Mark Read said: “We see in Finsbury Glover Hering a tremendous opportunity to establish a new global powerhouse in the strategic communications industry alongside a very talented and highly respected group of leaders. It also aligns with WPP’s strategy of creating simpler, stronger and more integrated client offers.”

Roland Rudd, co-Chairman and founder of Finsbury, commented: “Each of our firms is best in class and together create a new global standard for strategic advice and communications - we’d like to thank our clients for the trust they have placed in us as individual firms over the last decades.”

“We founded GPG with a highly entrepreneurial spirit, and we’re thrilled that we can now also offer a more sustainable value proposition to future generations,” said co-Chairman Carter Eskew.

CEO Alexander Geiser said: “With one global brand, balance sheet and governance, we are formally implementing what has long been reality for us. One firm, one team.”

The company will be headquartered in New York City, with operations in Abu Dhabi, Beijing, Berlin, Brussels, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, London, Los Angeles, Moscow, Riyadh, Shanghai, Singapore, Tokyo and Washington, D.C.

About Finsbury Glover Hering

Finsbury Glover Hering is a new preeminent global strategic communications advisory firm, headquartered in New York City, with almost 700 multidisciplinary experts across the world’s major financial, government, business and cultural centers. The company was formed through the merger of the leading strategic communications consultancies Finsbury, The Glover Park Group (GPG) and Hering Schuppener. The firm provides combined support in Government Relations & Policy and Advocacy, Corporate Reputation & Leadership Strategies, Crisis & Issues Management, Transaction & Financial Communications as well as Business Transformation, supported by Research and Insights, Digital Strategy, Media Planning and Creative Solutions.

Finsbury Glover Hering serves its global client base from offices in Abu Dhabi, Beijing, Berlin, Brussels, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, London, Los Angeles, Moscow, New York, Riyadh, Shanghai, Singapore, Tokyo and Washington, D.C.

Find more information visit www.fgh.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye